Seagen’s treatment of esophageal cancer was granted orphan designation by the FDA, according to a post to the agency’s website. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- 3 Stocks to Buy Today, 2/13/2023, According to Top Analysts
- Jefferies biotechnology analyst to hold an analyst/industry conference call
- SVB Securities downgrades Seagen to Market Perform, lowers price target to $141
- Seagen downgraded to Market Perform from Outperform at SVB Securities
- Truist sees potential pressure on Seagen’s Padcev in Q4